Business Context and Reporting Period
This Form 8-K Current Report was filed by Apimeds Pharmaceuticals US, Inc. on December 10, 2025, covering events occurring on December 5, 2025. The company is incorporated in Delaware and its common stock trades on NYSE American LLC under the symbol APUS. The registrant is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
Under Item 5.02, the Company reported the following material changes to its Board of Directors:
- Dr. Vin Menon resigned from his position as a Director.
- Amir A. Dossal resigned from his position as an Independent Director.
- The Company explicitly stated that these resignations were not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the nature of the director resignations.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following the resignations of Dr. Menon and Mr. Dossal.
- Confirm whether Dr. Vin Menon retains his role as Chief Executive Officer, as he signed the report in that capacity despite resigning as a Director.
- Review subsequent filings for any announcements regarding the appointment of new directors to fill the vacancies.